Obiri N I, Leland P, Murata T, Debinski W, Puri R K
Laboratory of Molecular Tumor Biology, Division of Cellular and Gene Therapies, Food and Drug Administration, Center for Biologics Evaluation and Research, Bethesda, MD 20892, USA.
J Immunol. 1997 Jan 15;158(2):756-64.
We have reported on the expression and characteristics of IL-13R and have demonstrated that IL-13 competes for IL-4 binding while IL-4 did not compete for the IL-13 binding on some cell types. Based on these observations, and the size of IL-13 and IL-4 cross-linked proteins, we concluded that the receptor for IL-13 is complex and shares a subunit with the receptor for IL-4. To explore the complexity of the IL-13R, a wide variety of cell types was examined for IL-13 and IL-4 binding. We report in this work that IL-4 does not always bind well to cells that bind IL-13, but the reverse is also true. We also found that IL-4 can compete more effectively for IL-13 binding than IL-13 itself. Cross-linking studies support these observations and demonstrate that 125I-labeled IL-13 bound exclusively to a single 65- to 70-kDa protein in MA-RCC and U251 cells, while in TF-1 cells it cross-linked to two membrane proteins of 65 to 70 kDa and 140 kDa. Furthermore, by using a chimeric protein composed of IL-13 and Pseudomonas exotoxin A, we observed that IL-4 neutralized the cytotoxicity of the IL-13 toxin on COS-7 cells by blocking a common form of the two cytokine receptors. We propose that the 65- to 70-kDa form of the IL-13R is the predominant common component shared between IL-13 and IL-4R. However, the primary IL-4 binding (p140) protein also participates in the formation of the IL-13R complex in some cell types. In addition, the gamma(c) or another interactive subunit may influence IL-13 binding to its receptor complex. Thus, we propose that there are at least four forms of IL-13R.
我们已报道了IL-13R的表达及特性,并证明IL-13能竞争IL-4的结合位点,而在某些细胞类型中IL-4并不竞争IL-13的结合位点。基于这些观察结果以及IL-13和IL-4交联蛋白的大小,我们得出结论,IL-13受体是复杂的,且与IL-4受体共享一个亚基。为探究IL-13R的复杂性,我们检测了多种细胞类型对IL-13和IL-4的结合情况。我们在这项研究中报告称,IL-4并不总是能很好地结合到能结合IL-13的细胞上,反之亦然。我们还发现,IL-4比IL-13自身更能有效地竞争IL-13的结合位点。交联研究支持了这些观察结果,并表明125I标记的IL-13在MA-RCC和U251细胞中仅与一种65至70 kDa的单一蛋白结合,而在TF-1细胞中它与65至70 kDa和140 kDa的两种膜蛋白交联。此外,通过使用由IL-13和铜绿假单胞菌外毒素A组成的嵌合蛋白,我们观察到IL-4通过阻断两种细胞因子受体的共同形式来中和IL-13毒素对COS-7细胞的细胞毒性。我们提出,65至70 kDa形式的IL-13R是IL-13和IL-4R之间共享的主要共同成分。然而,主要的IL-4结合(p140)蛋白在某些细胞类型中也参与了IL-13R复合物的形成。此外,γ(c)或另一个相互作用亚基可能会影响IL-13与其受体复合物的结合。因此,我们提出至少存在四种形式的IL-13R。